Regression of tumors in guinea pigs after treatment with synthetic muramyl dipeptides and trehalose dimycolate.
A high incidence of tumor regression was observed in guinea pigs bearing transplantable, line-10 hepatocellular carcinomas when synthetic muramyl dipeptides combined with trehalose dimycolate in oil-in-water emulsions were injected directly into the tumors. These compounds are promising candidates to replace viable bacillus Calmette-Guérin in cancer immunotherapy in humans and animals.
D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000008:administration & dosage / Q000627:therapeutic use*; D000818:Animals; D003311:Cord Factors / Q000008:administration & dosage / Q000627:therapeutic use*; D004338:Drug Combinations; D004655:Emulsions; D006017:Glycolipids / Q000627:therapeutic use*; D006020:Glycopeptides / Q000627:therapeutic use*; D007167:Immunotherapy; D008114:Liver Neoplasms, Experimental / Q000628:therapy*; D008207:Lymphatic Metastasis; D013329:Structure-Activity Relationship
D003311:Cord Factors; D004338:Drug Combinations; D004655:Emulsions; D006017:Glycolipids; D006020:Glycopeptides; D000119:Acetylmuramyl-Alanyl-Isoglutamine